Novartis Investigative Site

Svidník, Slovak Republic 08901

0 studies enrolling now · 6 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure With Reduced Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Hypertension

Studies at this site

• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed